3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
72
Neoplasms
7
Neoplasm Metastasis
7
Breast Diseases
5
Neoplasms by Site
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasm Female
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Carcinoma In Situ
1
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Anastrozole
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled